Alvotech
ALVO · Nasdaq · Luxembourg
Share price · ALVO
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ALVO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 13 Nov 2026-10.3%
- Day beforeAlvotech: 6-K filing
- 5 Oct 2026+12.1%
- 18 Sep 2026+9.9%
Nothing announced by ALVO that day or the session before.
- 24 Aug 2026+18.5%
- Day beforeAlvotech: 6-K filing
- 31 Jul 2026+15.4%
Nothing announced by ALVO that day or the session before.
- 29 Jul 2026+13.9%
- 22 Jun 2026-6.9%
- Day beforeAlvotech: 6-K filing
- 8 Jun 2026+19.8%
- 4 Jun 2026+19.1%
- 11 May 2026+10.1%
Share of unusual movement by asset
For each asset, the share of ALVO's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 55% |
| Sessions with no dated event | — | 45% |
No dated announcements about its assets since 3 Sep 2025.
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | TNF-alphaMonoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid ArthritisHidradenitis SuppurativaNon-Infectious Uveitis Ulcerative Colitis, Crohn's Disease | |
| Approved | IL-12 p40Monoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis Ulcerative Colitis, Crohn's Disease | |
| Preclinical / Unstaged | VEGF-AProtein / enzyme therapeutic | Age-Related Macular Degeneration | |
| Preclinical / Unstaged | VEGF-AProtein / enzyme therapeutic | Age-Related Macular Degeneration |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (2)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | $306M | $93M | $151M | — | report ↗ |
View 1 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-H1 | $236M | $97M | $11M | $77M | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $586M | $184M | $172M | —-$50M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $490M | $171M | $51M | $58M-$237M operating cash flow | report ↗ |
| 2023-FY | $91M | $211M | $11M | $138M-$312M operating cash flow | report ↗ |
| 2022-FY | $83M | $181M | $66M | $128M-$312M operating cash flow | report ↗ |
| 2021-FY | $37M | $191M | $18M | $25M-$228M operating cash flow | report ↗ |
Insider transactions
This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.